Abstract
The objective of the present study was to investigate the effects of β-conglycinin and soya isoflavones on diabetic nephropathy (DN). DN was induced by an intravenous injection of streptozotocin (25 mg/kg) in spontaneously hypertensive rats. DN rats were divided into a non-diabetic group (C, control group) and three DN groups (D, DN with control diet; B, DN+control diet with one-eighth of casein replaced by β-conglycinin as the protein source; and I, DN+control diet with 0·01 % soya isoflavones). After a 4-week experimental period, we found that fasting blood sugar and plasma and kidney advanced glycation end product levels and 24 h urinary protein excretion of the B group were significantly lower than those of the D group and insulin sensitivity and nephrin expression of the B group were significantly higher than those of the D group. In addition, systolic blood pressure, angiotensin-converting enzyme activity, angiotensin II level and plasma TAG level of the B group were significantly lower than those of the D group, whereas only the levels of plasma TAG and thiobarbituric acid-reactive substances of the I group were lower than those of the D group. In conclusion, β-conglycinin may be beneficial for retarding DN progression and this effect cannot be completely explained by its isoflavone content.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiotensin II / blood
-
Animals
-
Antigens, Plant / pharmacology
-
Antigens, Plant / therapeutic use*
-
Blood Glucose / metabolism
-
Blood Pressure / drug effects
-
Diabetes Mellitus, Experimental / complications
-
Diabetes Mellitus, Experimental / diet therapy
-
Diabetes Mellitus, Experimental / metabolism
-
Diabetes Mellitus, Experimental / physiopathology
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / diet therapy
-
Diabetes Mellitus, Type 2 / metabolism
-
Diabetes Mellitus, Type 2 / physiopathology
-
Diabetic Nephropathies / diet therapy*
-
Diabetic Nephropathies / metabolism
-
Diabetic Nephropathies / physiopathology
-
Dietary Proteins / pharmacology
-
Dietary Proteins / therapeutic use*
-
Globulins / pharmacology
-
Globulins / therapeutic use*
-
Glycation End Products, Advanced / metabolism
-
Glycine max / chemistry*
-
Insulin Resistance
-
Isoflavones / pharmacology*
-
Kidney / drug effects*
-
Kidney / metabolism
-
Kidney / physiopathology
-
Male
-
Membrane Proteins / metabolism*
-
Peptidyl-Dipeptidase A / metabolism
-
Phytotherapy
-
Plant Preparations / pharmacology
-
Plant Preparations / therapeutic use
-
Rats
-
Rats, Inbred SHR
-
Seed Storage Proteins / pharmacology
-
Seed Storage Proteins / therapeutic use*
-
Soybean Proteins / pharmacology
-
Soybean Proteins / therapeutic use*
-
Thiobarbituric Acid Reactive Substances
-
Triglycerides / blood
Substances
-
Antigens, Plant
-
Blood Glucose
-
Dietary Proteins
-
Globulins
-
Glycation End Products, Advanced
-
Isoflavones
-
Membrane Proteins
-
Plant Preparations
-
Seed Storage Proteins
-
Soybean Proteins
-
Thiobarbituric Acid Reactive Substances
-
Triglycerides
-
beta-conglycinin protein, Glycine max
-
nephrin
-
Angiotensin II
-
Peptidyl-Dipeptidase A